Get the Stockscreener App
2.89
3.99%
-0.12
Cadrenal Therapeutics Inc stock is traded at $2.89, with a volume of 40,788.
It is down -3.99% in the last 24 hours and down -30.19% over the past month.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
See More
Previous Close:
$3.01
Open:
$3.02
24h Volume:
40,788
Relative Volume:
0.58
Market Cap:
$8.90M
Revenue:
-
Net Income/Loss:
$-11.89M
P/E Ratio:
-0.5132
EPS:
-5.6317
Net Cash Flow:
$-10.96M
1W Performance:
-19.72%
1M Performance:
-30.19%
6M Performance:
-64.63%
1Y Performance:
-77.77%
1-Day Range:
$2.89
$3.185
1-Week Range:
$2.89
$3.665
52-Week Range:
$2.55
$14.64
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
2.89 | 8.90M | 0 | -11.89M | -10.96M | -5.6317 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Cadrenal Therapeutics (CVKD) Chief Medical Officer James Ferguson to step down July 31, 2026 - Stock Titan
Cadrenal Therapeutics, Inc. Announces Resignation of James J. Ferguson III from Chief Medical Officer Role, Effective July 31, 2026 - marketscreener.com
Cadrenal Therapeutics (CVKD) Declines 5.67% as Stock Tests Key Support at $3.00Ichimoku Cloud - dars.gov.et
CVKD Q1 2026 Earnings: Narrower-than-expected loss drives positive market reactionEarnings Weakness Phase - dars.gov.et
Cadrenal Therapeutics Secures Private Placement to Extend Runway - The Globe and Mail
Cadrenal (CVKD) CEO sells 7,400 shares, retains direct and trust stakes - Stock Titan
Cadrenal Therapeutics CEO sells $22,422 in stock By Investing.com - Investing.com South Africa
Cadrenal Therapeutics CEO sells $22,422 in stock - Investing.com
Form 4 Cadrenal Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
(CVKD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants - TradingView
Cadrenal Therapeutics (NASDAQ: CVKD) lines up up to $8.8M via private placement - Stock Titan
Cadrenal Therapeutics Enters Upto $8.8 Mln Private Placement To Extend Cash Runway; Stock Down - RTTNews
Cadrenal raises $3M now, with $5.8M more possible from warrants - Stock Titan
Cadrenal Therapeutics raises $3 million in private placement - Investing.com
Cadrenal Therapeutics raises $3 million in private placement By Investing.com - Investing.com Australia
Cadrenal Therapeutics Announces $3 Million Private Placement with Potential Additional $5.8 Million from Warrants - Quiver Quantitative
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Cadrenal Therapeutics Board Member Steven Zelenkofske Resigns - Moomoo
Cadrenal Therapeutics Appoints Interim CFO John Sharp Under Master Services Agreement with Lohman & Associates - Minichart
Cadrenal Therapeutics Names Sharp Interim CFO - Moomoo
Cadrenal Names Interim CFO, Realigns Board Structure - TipRanks
Cadrenal Therapeutics, Inc. announced that it expects to receive $3 million in funding - marketscreener.com
Cadrenal Therapeutics (NASDAQ: CVKD) names interim CFO and realigns board classes - Stock Titan
Cadrenal Therapeutics, Inc. Announces Board and Committee Changes - marketscreener.com
Cadrenal therapeutics CEO Pham sells $33,919 in stock By Investing.com - Investing.com South Africa
Form 4 Cadrenal Therapeutics Inc For: 26 June By Investing.com - Investing.com UK
Price to earnings forward of Cadrenal Therapeutics, Inc. – NASDAQ:CVKD - TradingView
Price to sales forward of Cadrenal Therapeutics, Inc. – NASDAQ:CVKD - TradingView
Enterprise value to EBITDA forward of Cadrenal Therapeutics, Inc. – NASDAQ:CVKD - TradingView
Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 11,156 shares under 10b5-1 plan - Stock Titan
Cadrenal therapeutics CEO Pham sells $33,919 in stock - Investing.com
Cadrenal Therapeutics, Inc. Actuals & Estimates (NASDAQ:CVKD) - TradingView
CVKD Forecast — Price Target — Prediction for 2027 - TradingView
Cadrenal Therapeutics chairman and CEO Pham sells $39,829 in stock. By Investing.com - Investing.com South Africa
Cadrenal Therapeutics chairman and CEO Pham sells $39,829 in stock. - Investing.com
Form 4 Cadrenal Therapeutics Inc For: 24 June By Investing.com - Investing.com Australia
Cadrenal (CVKD) CEO Quang Pham sells 11,444 shares in planned 10b5-1 trades - Stock Titan
Cadrenal’s HIT drug data selected for presentation at Paris congress - Investing.com UK
Cadrenal’s HIT drug data selected for presentation at Paris congress By Investing.com - Investing.com South Africa
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cadrenal Therapeutics Inc Stock (CVKD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 26 '26 |
Sale |
3.05 |
9,029 |
27,538 |
105,989 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 25 '26 |
Sale |
3.00 |
2,127 |
6,381 |
115,018 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 22 '26 |
Sale |
3.55 |
9,167 |
32,543 |
119,422 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 23 '26 |
Sale |
3.20 |
2,277 |
7,286 |
117,145 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 16 '26 |
Sale |
3.18 |
3,613 |
11,489 |
129,102 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 17 '26 |
Sale |
3.16 |
513 |
1,621 |
128,589 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 12 '26 |
Sale |
3.94 |
12,996 |
51,204 |
136,381 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 15 '26 |
Sale |
3.58 |
3,666 |
13,124 |
132,715 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 11 '26 |
Sale |
4.12 |
1,462 |
6,023 |
149,377 |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):